ENT Biotech Solutions recently secured $100,000 in seed capital from the Michigan Pre-Seed Fund
2.0, which is part of a $1 million angel round for the TechTown-based
"We are in the process of closing it," says Andrea Roumell Dickson, CEO of ENT Biotech Solutions
The two-year-old startup is developing the Elasso, a single-use, disposable device designed as a cost-effective too for reducing the tedious nature of adenoid and tonsil surgery. The one-step tool cuts, cauterizes, and removes tissue, combining the advantages of heating and cutting technologies.
ENT Biotech Solutions is currently waiting for a clearance from the FDA to move ahead with commercialization. That clearance could come as soon as this fall.
"As soon as we receive that we have a green light to manufacture. Our tooling is already cut," Roumell Dickson says. "We are able to very rapidly ramp up for production."
Source: Andrea Roumell Dickson, CEO of ENT Biotech Solutions
Writer: Jon Zemke
Read more about Metro Detroit's growing entrepreneurial ecosystem at SEMichiganStartup.com.